Advertisement

Urosepsis-Pathogenesis and Treatment

  • Samir Bidnur
  • Ryan K. Flannigan

Abstract

Urosepsis is a life-threatening infection that results from the interaction of bacteria and bacterial products with the host immune system, resulting in a clinically unstable patient. Pathogen factors include the virulence of particular bacterial strains/subtypes which produce toxins, most commonly components of the bacterial cell wall, that amplify and exaggerate the host immune response. Patient factors that contribute to the development of urosepsis include a compromised immune system incapable of effectively clearing infection, as seen in patients with uncontrolled HIV or patients taking chronic immunosuppression (i.e. chronic steroid use). Certain urologic conditions, specifically the obstruction of urinary flow secondary to urolithiasis or benign prostatic hyperplasia (BPH), can result in the rapid development of urosepsis. Successful management of sepsis requires early identification of clinical sepsis, prompt fluid resuscitation and administration of antibiotics, and relief of obstruction.

Keywords

Source Control Renal Abscess Sepsis Mortality Emphysematous Pyelonephritis Acute Bacterial Prostatitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Wagenlehner FM, Pilatz A, Weidner W. Urosepsis–from the view of the urologist. Int J Antimicrob Agents. 2011;38(Suppl):51–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Brun-Buisson C. The epidemiology of the systemic inflammatory response. Intensive Care Med. 2000;26 Suppl 1:S64–74.CrossRefPubMedGoogle Scholar
  3. 3.
    Serniak PS, et al. [The diagnosis of urosepsis]. Urol Nefrol (Mosk). 1990;(4):9–13.Google Scholar
  4. 4.
    Rosenthal EJ. Epidemiology of septicaemia pathogens. Dtsch Med Wochenschr. 2002;127:2435–40.CrossRefPubMedGoogle Scholar
  5. 5.
    Johansen TE, et al. Hospital acquired urinary tract infections in urology departments: pathogens, susceptibility and use of antibiotics. Data from the PEP and PEAP-studies. Int J Antimicrob Agents. 2006;28 Suppl 1:S91–107.CrossRefPubMedGoogle Scholar
  6. 6.
    Tapper H, Herwald H. Modulation of hemostatic mechanisms in bacterial infectious diseases. Blood. 2000;96:2329–37.PubMedGoogle Scholar
  7. 7.
    Joel Gustavo Gómez-Núñez UMA, Fernández F, Gutiérrez-Aceves J, López-Marín LM, Loske AM. Infected urinary stones, endotoxins and urosepsis. Clinical management of complicated urinary tract infection. InTech; 2011.Google Scholar
  8. 8.
    Triantafilou M, Triantafilou K. The dynamics of LPS recognition: complex orchestration of multiple receptors. J Endotoxin Res. 2005;11:5–11.PubMedGoogle Scholar
  9. 9.
    Taudorf S, Krabbe KS, Berg RM, Pedersen BK, Moller K. Human models of low-grade inflammation: bolus versus continuous infusion of endotoxin. Clin Vaccine Immunol. 2007;14:250–5.PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Calandra T, Glauser MP, Schellekens J, Verhoef J. Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial. J Infect Dis. 1988;158:312–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Girardin E, Grau GE, Dayer JM, Roux-Lombard P, Lambert PH. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med. 1988;319:397–400.CrossRefPubMedGoogle Scholar
  12. 12.
    Rivers E, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368–77.CrossRefPubMedGoogle Scholar
  13. 13.
    Hoddick W, Jeffrey RB, Goldberg HI, Federle MP, Laing FC. CT and sonography of severe renal and perirenal infections. AJR Am J Roentgenol. 1983;140:517–20.CrossRefPubMedGoogle Scholar
  14. 14.
    Christoph F, Weikert S, Muller M, Miller K, Schrader M. How septic is urosepsis? Clinical course of infected hydronephrosis and therapeutic strategies. World J Urol. 2005;23:243–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Kreger BE, Craven DE, McCabe WR. Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med. 1980;68:344–55.CrossRefPubMedGoogle Scholar
  16. 16.
    Kreger BE, Craven DE, Carling PC, McCabe WR. Gram-negative bacteremia. III. Reassessment of etiology, epidemiology and ecology in 612 patients. Am J Med. 1980;68:332–43.CrossRefPubMedGoogle Scholar
  17. 17.
    Singh N, Yu VL. Rational empiric antibiotic prescription in the ICU. Chest. 2000;117:1496–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Byl B, et al. Ceftazidime- and imipenem-induced endotoxin release during treatment of gram-negative infections. Eur J Clin Microbiol Infect Dis. 2001;20:804–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Luchi M, et al. A comparative trial of imipenem versus ceftazidime in the release of endotoxin and cytokine generation in patients with gram-negative urosepsis. Urosepsis Study Group. J Endotoxin Res. 2000;6:25–31.CrossRefPubMedGoogle Scholar
  20. 20.
    Magill SS, et al. The association between anatomic site of Candida colonization, invasive candidiasis, and mortality in critically ill surgical patients. Diagn Microbiol Infect Dis. 2006;55:293–301.CrossRefPubMedGoogle Scholar
  21. 21.
    Binelli CA, et al. Investigation of the possible association between nosocomial candiduria and candidaemia. Clin Microbiol Infect. 2006;12:538–43.CrossRefPubMedGoogle Scholar
  22. 22.
    Guidet B, et al. Incidence and impact of organ dysfunctions associated with sepsis. Chest. 2005;127:942–51.CrossRefPubMedGoogle Scholar
  23. 23.
    Bin C, et al. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli. Diagn Microbiol Infect Dis. 2006;56:351–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Alhambra A, Cuadros JA, Cacho J, Gomez-Garces JL, Alos JI. In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics. J Antimicrob Chemother. 2004;53:1090–4.CrossRefPubMedGoogle Scholar
  25. 25.
    Gorelov S, Zedan F, Startsev V. The choice of urinary drainage in patients with ureteral calculi of solitary kidneys. Arch Ital Urol Androl. 2004;76:56–8.PubMedGoogle Scholar
  26. 26.
    Hsu JM, Chen M, Lin WC, Chang HK, Yang S. Ureteroscopic management of sepsis associated with ureteral stone impaction: is it still contraindicated? Urol Int. 2005;74:319–22.CrossRefPubMedGoogle Scholar
  27. 27.
    Malek RS, Elder JS. Xanthogranulomatous pyelonephritis: a critical analysis of 26 cases and of the literature. J Urol. 1978;119:589–93.PubMedGoogle Scholar
  28. 28.
    Hudson MA, Weyman PJ, van der Vliet AH, Catalona WJ. Emphysematous pyelonephritis: successful management by percutaneous drainage. J Urol. 1986;136:884–6.PubMedGoogle Scholar
  29. 29.
    Dutta D, et al. Conservative management of severe bilateral emphysematous pyelonephritis: Case series and review of literature. Indian J Endocrinol Metab. 2013;17:S329–32.PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Shu T, Green JM, Orihuela E. Renal and perirenal abscesses in patients with otherwise anatomically normal urinary tracts. J Urol. 2004;172:148–50.CrossRefPubMedGoogle Scholar
  31. 31.
    Arrabal-Polo MA, Jimenez-Pacheco A, Arrabal-Martin M. Percutaneous drainage of prostatic abscess: case report and literature review. Urol Int. 2012;88:118–20.CrossRefPubMedGoogle Scholar
  32. 32.
    Susanibar Napuri LF, et al. Prostatic abscess: diagnosis and treatment of an infrequent urological entity. Arch Esp Urol. 2011;64:62–6.PubMedGoogle Scholar
  33. 33.
    Shyam DC, Rapsang AG. Fournier’s gangrene. Surgeon. 2013;11:222–32.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Department of Urological SciencesUniversity of British ColumbiaVancouverCanada
  2. 2.Department of UrologyUniversity of British ColumbiaVancouverCanada

Personalised recommendations